Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) Target Price at $21.43

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have earned an average recommendation of “Hold” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $22.80.

A number of equities analysts have recently weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research report on Wednesday, November 6th. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a research note on Monday, December 2nd. TD Cowen reiterated a “buy” rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Piper Sandler restated a “neutral” rating and issued a $21.00 target price (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, Morgan Stanley started coverage on Hims & Hers Health in a research note on Tuesday. They set an “overweight” rating and a $42.00 price target for the company.

Hims & Hers Health Trading Down 0.6 %

Shares of NYSE HIMS opened at $26.20 on Monday. The firm has a market capitalization of $5.72 billion, a P/E ratio of 59.55 and a beta of 1.25. The firm’s 50-day moving average price is $25.78 and its 200-day moving average price is $21.27. Hims & Hers Health has a 1-year low of $8.09 and a 1-year high of $35.02.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The business had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm’s revenue was up 77.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.04) EPS. Equities research analysts forecast that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Activity

In other Hims & Hers Health news, COO Melissa Baird sold 58,750 shares of the firm’s stock in a transaction on Monday, October 7th. The stock was sold at an average price of $19.57, for a total value of $1,149,737.50. Following the completion of the sale, the chief operating officer now directly owns 630,166 shares of the company’s stock, valued at $12,332,348.62. This trade represents a 8.53 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $20.88, for a total value of $3,943,981.44. Following the completion of the sale, the chief executive officer now owns 67,015 shares in the company, valued at approximately $1,399,273.20. The trade was a 73.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,085,157 shares of company stock valued at $26,765,193 in the last ninety days. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC boosted its holdings in Hims & Hers Health by 679.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares during the period. Legacy Capital Group California Inc. purchased a new position in shares of Hims & Hers Health in the second quarter valued at $1,699,000. Bank of New York Mellon Corp raised its stake in shares of Hims & Hers Health by 67.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 678,602 shares of the company’s stock valued at $13,701,000 after purchasing an additional 273,473 shares during the period. State of Michigan Retirement System lifted its holdings in Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock worth $10,095,000 after purchasing an additional 320,000 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in Hims & Hers Health by 322.9% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 52,312 shares of the company’s stock worth $1,056,000 after purchasing an additional 39,943 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.